18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis

Internal Medicine

Volumn 51, Issue 12, 2012, Pages 1613-1618

  Morita, Yoshikata ^a   Kuwagata, Shogo ^a   Kato, Noriko ^a   Tsujimura, Yoshinori ^a   Mizutani, Hiromi ^a   Suehiro, Mitsuhiro ^a   Isono, Motohide ^a  

^a Otsu Municipal Hospital   (Japan)

Author keywords

18F FDG PET CT; Anti CADM 140 antibody; Dermatomyositis; Interstitial lung disease

Indexed keywords

AUTOANTIBODY; CADM 140 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FERRITIN; FLUORODEOXYGLUCOSE F 18; FRUCTOSE BISPHOSPHATE ALDOLASE; MYOGLOBIN; PREDNISOLONE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ACUTE LUNG INJURY; ACUTE RESPIRATORY FAILURE; AGED; ANTIBODY DETECTION; ARTERIAL GAS; ARTICLE; AUTOPSY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DEATH; DERMATOMYOSITIS; DISEASE COURSE; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; ERYTHEMA; FEMALE; FEVER; HUMAN; HYPERKERATOSIS; INTERSTITIAL LUNG DISEASE; LUNG ASPERGILLOSIS; LUNG AUSCULTATION; MALAISE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; FATALITY; SCINTISCANNING;

AGED; DERMATOMYOSITIS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FATAL OUTCOME; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG DISEASES, INTERSTITIAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84862989057     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6813     Document Type: Article

References (20)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362: 971-982, 2003.
2. Plotz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME. Current concepts in the idiopathic inflammatory myopathies: poly-myositis, dermatomyositis, and related disorders. Ann Intern Med 111: 143-157, 1989.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.
4. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17: 701-706, 2005.
5. Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49: 1354-1360, 2010.
6. Mii S, Kobayashi R, Nakano T, et al. A histopathologic study of mechanic's hands associated with dermatomyositis: a report of five cases. Int J Dermatol 48: 1177-1182, 2009.
7. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.
8. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 19: 523-529, 2007.
9. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56: 255-286, 1977.
10. Torok L, Danko K, Cserni G, Szucs G. PM-SCL autoantibody positive scleroderma with polymyositis (mechanic's hand: clinical aid in the diagnosis). J Eur Acad Dermatol Venereol 18: 356-359, 2004.
11. Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol 17: 1058-1063, 1990.
12. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophago-cytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 135: 299-314, 2005.
13. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermato-myopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626-636, 2002.
14. Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 73: 197-202, 2006.
15. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fi-brosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 50: 538-545, 2009.
16. Umeda Y, Demura Y, Ishizaki T, et al. Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging 36: 1121-1130, 2009.
17. Tateishi U, Hasegawa T, Seki K, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and posi-tron emission tomography. Eur J Nucl Med Mol Imaging 33: 906-912, 2006.
18. Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Muller-Quernheim J. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration 70: 262-269, 2003.
19. 18F]2-fluoro-2-deoxyglucose positron emission tomography/computed tomography in predictingradiation pneumonitis. Chin Med J (Engl) 122: 1311-1315, 2009.
20. 18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 50: 904-911, 2009.